Neurochem Gets FDA Priority Review For AA Amyloidosis Drug
This article was originally published in The Pink Sheet Daily
Executive Summary
Filing for Fibrillex in Europe awaits accelerated orphan drug pathway, but could come in fall 2006.
You may also be interested in...
Neurochem Gets Second FDA “Approvable” Letter For Kiacta
FDA suggests that it may require an additional clinical efficacy trial with a p-value of 0.05 or less.
Neurochem Gets Second FDA “Approvable” Letter For Kiacta
FDA suggests that it may require an additional clinical efficacy trial with a p-value of 0.05 or less.
J&J/Neurochem Kiacta Is “Approvable” For Secondary Amyloidosis
Firms plan to submit response based on existing studies in four to six weeks.